Trial Profile
Neoadjuvant Radiochemotherapy Combined with Panitumumab in Locally Advanced KRAS wild-type Rectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Antineoplastics
- Indications Rectal cancer
- Focus Therapeutic Use
- Acronyms NEOREC-1
- 06 May 2015 Status changed from suspended to completed as reported by ClinicalTrials.gov record.
- 06 May 2015 Status changed from suspended to completed as reported by ClinicalTrials.gov record.
- 10 Sep 2012 Planned End Date changed from 1 Apr 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.